United Asset Strategies Inc. boosted its stake in Johnson & Johnson (NYSE:JNJ) by 8.2% during the second quarter, Holdings Channel reports. The firm owned 5,664 shares of the company’s stock after buying an additional 428 shares during the period. United Asset Strategies Inc.’s holdings in Johnson & Johnson were worth $687,000 as of its most recent filing with the SEC.
A number of other large investors have also recently modified their holdings of the company. Americafirst Capital Management LLC bought a new stake in Johnson & Johnson during the second quarter worth $101,000. INR Advisory Services LLC bought a new stake in Johnson & Johnson during the second quarter worth $150,000. Capital Asset Advisory Services LLC bought a new stake in Johnson & Johnson during the second quarter worth $202,000. NewSquare Capital LLC raised its stake in Johnson & Johnson by 4.9% in the second quarter. NewSquare Capital LLC now owns 1,791 shares of the company’s stock worth $217,000 after buying an additional 83 shares during the period. Finally, Shayne & CO. LLC bought a new stake in Johnson & Johnson during the second quarter worth $219,000. 65.32% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson (NYSE:JNJ) traded down 0.12% during trading on Wednesday, hitting $118.68. The stock had a trading volume of 2,744,484 shares. The firm has a 50 day moving average of $119.00 and a 200-day moving average of $116.96. Johnson & Johnson has a 12 month low of $93.44 and a 12 month high of $126.07. The stock has a market cap of $324.69 billion, a price-to-earnings ratio of 22.12 and a beta of 0.62.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, July 19th. The company reported $1.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.68 by $0.06. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%. The company earned $18.50 billion during the quarter, compared to analysts’ expectations of $17.98 billion. Equities analysts predict that Johnson & Johnson will post $6.69 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd were paid a dividend of $0.80 per share. The ex-dividend date was Friday, August 19th. This represents a $3.20 annualized dividend and a yield of 2.69%. Johnson & Johnson’s dividend payout ratio is presently 60.15%.
A number of research firms have recently weighed in on JNJ. Leerink Swann reissued a “buy” rating on shares of Johnson & Johnson in a research note on Sunday, September 11th. Wells Fargo & Co. reissued a “buy” rating on shares of Johnson & Johnson in a research note on Monday, July 11th. BMO Capital Markets reissued an “outperform” rating and issued a $132.00 target price on shares of Johnson & Johnson in a research note on Wednesday, July 20th. Jefferies Group boosted their price target on Johnson & Johnson from $113.00 to $119.00 and gave the company a “hold” rating in a report on Thursday, August 4th. Finally, Deutsche Bank AG restated a “hold” rating and set a $142.00 price target (up previously from $125.00) on shares of Johnson & Johnson in a report on Thursday, July 21st. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eleven have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $120.19.
In other news, VP Dominic J. Caruso sold 41,146 shares of the stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total value of $5,143,661.46. Following the completion of the sale, the vice president now owns 157,819 shares of the company’s stock, valued at approximately $19,728,953.19. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CAO Ronald A. Kapusta sold 2,935 shares of the stock in a transaction that occurred on Friday, July 22nd. The shares were sold at an average price of $125.01, for a total transaction of $366,904.35. Following the completion of the sale, the chief accounting officer now directly owns 28,660 shares of the company’s stock, valued at approximately $3,582,786.60. The disclosure for this sale can be found here. Corporate insiders own 0.11% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.